Galmed Pharmaceuticals Earns Sell Rating from Analysts at StockNews.com
GLMD Stock | USD 2.88 0.17 5.57% |
About 65% of Galmed Pharmaceuticals' investor base is looking to short. The analysis of the overall investor sentiment regarding Galmed Pharmaceuticals suggests that many traders are alarmed. The current market sentiment, together with Galmed Pharmaceuticals' historical and current headlines, can help investors time the market. In addition, many technical investors use Galmed Pharmaceuticals stock news signals to limit their universe of possible portfolio assets.
Galmed |
StockNews.com started coverage on shares of Galmed Pharmaceuticals in a report published on Thursday morning. The firm issued a sell rating on the biopharmaceutical companys stock. Galmed Pharmaceuticals Price Performance Galmed Pharmaceuticals stock opened at 0.34 on Thursday. Galmed Pharmaceuticals has a 12-month low of 0.29 and a 12-month high of
Read at thelincolnianonline.com
Galmed Pharmaceuticals Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Galmed Pharmaceuticals can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Galmed Pharmaceuticals Fundamental Analysis
We analyze Galmed Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Galmed Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Galmed Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Employees
Number Of Employees Comparative Analysis
Galmed Pharmaceuticals is currently under evaluation in number of employees category among its peers. Number of Employees shows the total number of permanent full time and part time employees working for a given company and processed through its payroll.
Galmed Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Galmed Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Galmed Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Galmed Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Galmed Pharmaceuticals Related Equities
MBIO | Mustang Bio | 5.26 | ||||
LPTX | Leap Therapeutics | 4.43 | ||||
ADAP | Adaptimmune Therapeutics | 3.23 | ||||
MREO | Mereo BioPharma | 1.58 | ||||
ABEO | Abeona Therapeutics | 1.01 | ||||
ADVM | Adverum Biotechnologies | 0.68 | ||||
KOD | Kodiak Sciences | 1.48 | ||||
PDSB | PDS Biotechnology | 2.28 | ||||
PIRS | Pieris Pharmaceuticals | 2.35 | ||||
FBIO | Fortress Biotech | 2.83 | ||||
ACHL | Achilles Therapeutics | 2.86 | ||||
AFMD | Affimed NV | 2.93 | ||||
AKBA | Akebia Ther | 3.03 | ||||
FBIOP | Fortress Biotech | 3.32 | ||||
APTO | Aptose Biosciences | 5.26 |
Complementary Tools for Galmed Stock analysis
When running Galmed Pharmaceuticals' price analysis, check to measure Galmed Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galmed Pharmaceuticals is operating at the current time. Most of Galmed Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Galmed Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galmed Pharmaceuticals' price. Additionally, you may evaluate how the addition of Galmed Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |